Psychedelic Program for the Treatment of Mental Diseases

Published on

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided a scientific update on the advancement of its novel 5-HT2A psychedelic program for the treatment of mental diseases.

Published on Psychedelic, Mental Diseases, Biotechnology Company, Bright Minds Biosciences

To be informed of the latest articles, subscribe:
You might also like:
Solid Advice For Handling Your Issues With Depression
Solid Advice For Handling Your Issues With Depression
Have A Brighter Tomorrow With Bright Minds
Have A Brighter Tomorrow With Bright Minds
Is It A Good Idea To Invest In Bright Minds - Psychedelic Company Stocks Canada?
Is It A Good Idea To Invest In Bright Minds - Psychedelic Company Stocks Canada?
Everything About Psychedelic Drug And How It Works
Everything About Psychedelic Drug And How It Works
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
Is It A Good Idea To Invest In Bright Minds - Psychedelic Company Stocks Canada?
Comment on this post